Dr. Allan Goldman:

I might go back to the question about the innovation.

In children's health, in complex diseases and in a children's hospital such as CHI, we want to encourage innovation. It is part of the fabric of the organisation. We encourage multidisciplinary teams to get together and they do so naturally when there is a problem with a child. If that transpires and someone wants to learn more or innovate, it ends up going down a research line. There are two components: going through the research ethics process; and, if a new drug or device is being used, following the process to make sure it is approved. It would usually be a CE-marked device.